SG Americas Securities LLC Raises Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

SG Americas Securities LLC lifted its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 295.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,598 shares of the company's stock after purchasing an additional 4,931 shares during the period. SG Americas Securities LLC's holdings in PROCEPT BioRobotics were worth $531,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in PRCT. Values First Advisors Inc. acquired a new position in shares of PROCEPT BioRobotics in the third quarter worth about $27,000. Wilmington Savings Fund Society FSB acquired a new position in PROCEPT BioRobotics in the 3rd quarter worth about $64,000. Canton Hathaway LLC purchased a new position in PROCEPT BioRobotics during the third quarter worth approximately $66,000. Nisa Investment Advisors LLC boosted its position in PROCEPT BioRobotics by 178.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock worth $89,000 after purchasing an additional 713 shares in the last quarter. Finally, Sentry Investment Management LLC acquired a new stake in PROCEPT BioRobotics in the third quarter valued at approximately $120,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at PROCEPT BioRobotics

In related news, EVP Alaleh Nouri sold 28,092 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares in the company, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Reza Zadno sold 26,420 shares of the business's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $92.57, for a total transaction of $2,445,699.40. Following the completion of the transaction, the chief executive officer now owns 205,605 shares in the company, valued at $19,032,854.85. The trade was a 11.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 141,355 shares of company stock worth $13,571,048 in the last ninety days. Insiders own 17.40% of the company's stock.

Analysts Set New Price Targets

PRCT has been the topic of a number of recent analyst reports. Truist Financial reiterated a "buy" rating and set a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Jefferies Financial Group started coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. Wells Fargo & Company restated an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley initiated coverage on PROCEPT BioRobotics in a report on Monday, December 2nd. They issued an "overweight" rating and a $105.00 price objective on the stock. Finally, Piper Sandler reiterated an "overweight" rating and set a $75.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $97.86.

PROCEPT BioRobotics Price Performance

PRCT traded up $0.34 on Tuesday, reaching $71.59. 637,214 shares of the company's stock were exchanged, compared to its average volume of 900,642. The stock has a market cap of $3.74 billion, a PE ratio of -36.71 and a beta of 1.03. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81. The stock's fifty day moving average price is $83.36 and its 200-day moving average price is $79.53.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).